BOSTON, Dec. 22, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company generated $27,455.52 and $30,103.00 in sales for the months of October and November 2011 respectively. Sales for the two month period were primarily driven by the Company's MammoView® Instrument line accounting for 38.9% of the $57,588.52 in sales revenue for October and November.
Total mammary ductoscopy sales increased 183% from $7925.00 in October to $14,490.00 in November. Solos' MammoView® Instrument line contains 13 different Breast Endoscopy Components which are all featured on the Company's website http://www.solosendoscopy.com/newproductline.html. The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates.
"We had reported in August how pleased we were with the increase in demand for our MammoView instrument line," stated Bob Segersten, President of Solos Endoscopy, Inc. "The mammary ductoscopy sales in the third quarter as well as for October and November are something the Company will continue to build on as we enter 2012."
The Company recently announced that it finished the 3rd Quarter with a Net Profit of $73,895. Solos Endoscopy has consummated agreements which resulted in the Forgiveness of debt of $299,082 for the Three Months period ending September 30, 2011. The signed settlement agreement and new consulting agreement result in a reduction of ongoing expenses by approximately $40,000 per quarter.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Source: Solos Endoscopy, Inc.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2010 PR Newswire.
All rights reserved